Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 85 years old
• People who have been diagnosed with a grade IV brain tumour called glioblastoma (including types such as gliosarcoma or giant cell glioblastoma), confirmed by laboratory testing of tumour tissue
• People whose tumour has come back in a single area that is no larger than 3cm and shows up on a specific type of MRI scan (with contrast dye)
• People whose tumour cannot be surgically removed — for example, because they have declined surgery, are not medically suitable for it, or because the tumour is in a location that makes surgery too risky
• People who previously received a standard course of brain radiation therapy (50.4–60 Gy in standard-sized daily doses) along with a chemotherapy drug called temozolomide (confirm with trial site if a different radiation schedule was used)
• People who finished their previous radiation treatment at least 4 months before joining the trial, and whose tumour has been confirmed to have grown or returned based on standard imaging criteria
• People whose tumour can be measured using standard imaging criteria
• People whose life expectancy is estimated to be more than 6 months
• People whose tumour is in a location suitable for the trial's treatment device (DaRT sources)
• People who have either had recent partial surgery or a biopsy of the returned tumour (at least 6 weeks before joining), or have clear scan evidence of tumour regrowth on a contrast MRI taken within 21 days before joining the trial
• People who have recovered from side effects of previous treatments, and have waited at least 4 weeks since their last chemotherapy or experimental treatment (or at least 6 weeks for certain chemotherapy drugs such as Carmustine, Fotemustine, or Lomustine)
• People with a functional ability score (Karnofsky Performance Score) of at least 60, measured within 14 days before joining the trial
• People whose recent blood test results (taken within 14 days before starting treatment) show adequate levels of white blood cells, platelets, and haemoglobin
• People whose recent blood test results (taken within 14 days before starting treatment) show liver enzyme and bilirubin levels within acceptable ranges
• People who agree to use effective contraception during the trial and for up to 3 months after treatment ends (applies to both male and female participants)
• People who have been fully informed about the trial, agree to take part, and have signed the consent form before any trial-related activities begin

Who may not be able to join:

• People who cannot safely have an MRI scan (note: heart devices that are MRI-compatible are allowed)
• People whose tumour has returned more than 3 times according to standard imaging criteria
• People with a known or inherited tendency to bleed
• People with signs that the tumour may have spread to certain other areas of the brain or nervous system (confirm with trial site)
• People currently receiving chemotherapy or other systemic treatments not permitted under this trial's guidelines
• People who have received a specific type of blood vessel-targeting drug (VEGF or VEGFR inhibitor) within the past 6 weeks
• People with a weakened immune system due to an organ transplant or AIDS
• People who have previously had an allergic reaction to the trial drugs
• People with a history of a severe sudden rise in blood pressure or related brain condition
• People with uncontrolled high blood pressure (above 150/90 mmHg)
• People with a history of a non-healing wound, ulcer, serious gastrointestinal bleeding, significant injury, or bone fracture within the 90 days before joining
• People who are currently taking part in another interventional clinical trial (within the past 30 days) that may interfere with this trial's results
• People who, in the opinion of the trial investigators, are unlikely to be able to follow the trial requirements
• People who are pregnant or breastfeeding
• People with certain connective tissue diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis

Important: Always verify eligibility with the trial site directly before applying.